Illustrative image – not actual.Ranbaxy (Malaysia) Sdn Bhd, a subsidiary of Ranbaxy Laboratories has obtained approval from the Malaysia Government for setting up a greenfield manufacturing facility as an entry point project (EPP).
The company will be investing $40 million (approx Rs 228 crore) in the proposed project. It will manufacture dosage forms including tablets and capsules primarily in the Cariovascular, anti-diabetic, anti-infective, gastrointestinal segments. The facility will export products to markets like ASEAN, Middle East, Europe, Sri Lanka, China and other select countries.
